Although further study is warranted before its application in the clinical setting, the targeting of BAFF as a therapeutic strategy appears promising in the treatment of a subset of AHA patients, as well as of hemophilia A patients with refractory inhibitors presenting with elevated BAFF levels. The gene discussed is TNFSF13B; the disease is autoimmune hemolytic anemia.